🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — July 24, 2026

The overnight filing period from July 23-24, 2026, reveals a market dominated by transformative M&A activity, mixed earnings results, and significant insider selling. The most critical development is the creation of a top-three U.S. clean power platform via the Greenbacker/MN8 merger ($375M base purchase price, ~6.2 GW combined capacity), alongside SoundHound AI clearing all foreign regulatory hurdles for its LivePerson acquisition. Financial sector results are bifurcated: Flagstar Bank showed a dramatic YoY earnings turnaround (net income of $26M vs. a $78M loss), while Woori Financial posted strong QoQ net income growth (+60.5%) but declining revenue (-13.9% QoQ). A notable pattern of insider selling emerged, with executives at Cadence Design Systems, Viant Technology, and Kaspi.kz all executing pre-planned sales. Intel's Q2 results present a stark contrast: revenue grew 25% YoY to $16.1B and gross margins improved to 40.4%, but a massive $13.6B mark-to-market loss on escrowed shares drove a net loss of $11.0B, widening from a $2.9B loss a year ago. The period also saw two significant SPAC combinations close (Perceptive Capital/Freenome with $332.6M pro forma cash) and a major debt offering from Galaxy Digital ($3.5B in senior secured notes).

24 high priority 26 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 23, 2026

The July 23, 2026 digest covers two biosimilar approvals from small-cap sponsors, DR REDDYS LABS LTD for SITAGLIPTIN PHOSPHATE and RISING for HYDROCORTISONE, with no NMEs, biosimilars, or label expansions recorded. Both approvals are classified as FALLBACK type with neutral signals, indicating limited immediate investment impact. The absence of NMEs or breakthrough designations suggests a quiet period for high-value catalysts, while the biosimilar entries may pressure originator market shares in diabetes and corticosteroid segments. Key risk is the lack of commercial detail (peak sales, exclusivity, pricing) for both drugs, making revenue projections uncertain. The highest-conviction signal is the neutral rating on both approvals, reflecting low materiality for institutional portfolios.

2 total filings
· daily

Big Pharma Approvals — July 23, 2026

The July 23, 2026 approval period featured a single label expansion for Novartis' IPTACOPAN HYDROCHLORIDE (FABHALTA), classified as a 'Fallback' approval with a bullish signal. This is a low-volume period with zero NMEs, biosimilars, or standard label expansions, limiting sector-wide thematic signals. The highest-conviction signal is the Fabhalta label expansion, which strengthens Novartis' position in complement-mediated diseases but carries modest materiality given undisclosed peak sales and exclusivity details. The key risk is the lack of clarity on the specific indication and competitive dynamics, making this a watch-and-confirm event rather than a high-impact catalyst.

1 total filings
· daily

Orphan Drug Approvals — July 23, 2026

During the July 23, 2026 review period, the FDA approved two non-NME, non-biosimilar label expansions classified as 'FALLBACK' approvals—neither designating new molecular entities, priority review, breakthrough therapy, or orphan drug status. The approvals were for Novartis’s IPTACOPAN HYDROCHLORIDE (FABHALTA) and Mundipharma’s REZAFUNGIN ACETATE (REZZAYO). Both approvals are labeled as bullish with moderate strength/materiality scores, but the absence of breakthrough or priority designations, combined with a lack of disclosed commercial data (peak sales, pricing power, market position), significantly weakens the conviction signal. No dominant therapeutic area cluster emerges from these two distinct mechanisms, and the lack of NME or biosimilar activity suggests a quiet period for high-impact catalysts. The primary risk is the low-information environment around these label expansions, which limits actionable investment theses.

2 total filings
· daily

New Drug Approvals (Original) — July 23, 2026

The July 23, 2026 approval period yielded two biosimilar approvals (Sitagliptin Phosphate from Dr. Reddy's Labs and Hydrocortisone from Rising), with zero NMEs, zero label expansions, and zero biosimilars classified under the standard biosimilar stream. This is a low-velocity day with no therapeutic area clustering, as the approvals span metabolic (DPP-4 inhibitor) and endocrine (corticosteroid) categories. The highest-conviction signal is the Dr. Reddy's Sitagliptin Phosphate approval, which opens a new biosimilar entrant into the $3B+ Januvia market, though commercial data (peak sales, pricing) are NOT_DISCLOSED. The key risk is that both approvals are classified as 'FALLBACK' rather than standard biosimilar, suggesting potential interchangeability or manufacturing complexity issues that could limit market uptake.

2 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 23, 2026

This digest covers a single, large civilian contract from the Department of Health and Human Services (HHS) to the International AIDS Vaccine Initiative Inc. (IAVI) valued at $95.6 million obligated against a $166.9M ceiling. The contract is entirely civilian, focused on biodefense vaccine development (Marburg and Sudan ebolavirus), reflecting sustained HHS/BARDA investment in pandemic preparedness. The highest-conviction signal is a neutral one, as the fixed-price structure transfers significant performance risk to a nonprofit entity with limited financial buffers, while the long-term duration provides revenue visibility. A key risk is the execution risk on R&D milestones under a firm-fixed-price contract, which could strain IAVI's resources.

1 total filings
· daily

New Federal Contractors — July 23, 2026

The July 23, 2026 digest covers $1.28B in awards, with one-third defense-related and the bulk ($1.07B) going to Booz Allen Hamilton in a sole-source defense contract from GSA, signaling durable backlog despite limited competitive detail. The civilian side features a $120M NASA helium contract for Air Products and a $96M HHS/BARDA vaccine R&D award for IAVI, highlighting stable space infrastructure spending and biodefense funding, respectively. The highest-conviction signal is Booz Allen's massive award, which bolsters its defense backlog but carries execution risk due to unknown pricing terms. Key risk: Air Products' helium contract expires September 2025, creating a re-compete exposure for a multi-year revenue stream.

3 total filings
· daily

Significant Contract Modifications ($10M+) — July 23, 2026

The digest covers $1.28 billion in obligations from three contracts, with a 1:2 defense-to-civilian split. The dominant signal is a $1.07 billion sole-source modification for Booz Allen Hamilton from the General Services Administration, representing 83% of total value and a strong bullish indicator for defense services. A $120.3 million NASA contract for Air Products and Chemicals provides stable multi-year revenue for industrial gases, while a $95.6 million HHS/BARDA contract for IAVI carries high execution risk due to fixed-price R&D terms. Key risk includes potential protest vulnerability for the Booz Allen award and IAVI's nonprofit status limiting equity upside.

3 total filings
· daily

Contract Deobligations Alert — July 23, 2026

This digest covers $1.28 billion in total obligations across three contracts, with a 1/3 defense-related split. The dominant signal is a massive $1.07B sole-source defense award to Booz Allen Hamilton from the General Services Administration, representing 83% of total value and a high-conviction bullish signal for the company's competitive moat in defense consulting. Civilian awards include a $120.3M NASA helium supply contract to Air Products and Chemicals and a $95.6M BARDA vaccine R&D award to IAVI Inc., both offering multi-year revenue visibility but with differing risk profiles. Key risk: the Booz Allen award lacks pricing and competition details, raising execution risk if it is fixed-price or protest-vulnerable. Key watch item: NASA's option exercises on the Air Products contract for space launch infrastructure demand signals.

3 total filings
· daily

Contract Option Exercises — July 23, 2026

The July 23, 2026 contract option exercise stream totals $1.28 billion in obligations, with one-third defense-related and an average signal strength of 6.3/10. The dominant theme is a massive $1.07 billion sole-source-like award to Booz Allen Hamilton from the General Services Administration, likely defense-related, which overshadows two smaller civilian contracts. The highest-conviction signal is the Booz Allen award, but its lack of detail introduces uncertainty; the most actionable signal is Air Products' $120.3 million NASA helium contract, which provides stable, multi-year revenue from a critical space infrastructure role. Key risks include the opaque nature of the Booz Allen award and the high execution risk of IAVI's fixed-price vaccine R&D contract with HHS.

3 total filings
· daily

Federal Professional Services Contracts — July 23, 2026

The digest covers a single, highly material $1.07 billion defense contract awarded to Booz Allen Hamilton by the General Services Administration (GSA). This is a civilian-agency-administered contract with defense end-use, signaling robust demand for professional services from the Department of Defense. The contract is a sole-source award, indicating a strong competitive moat for Booz Allen. The key risk is the lack of pricing and competition details, which could obscure margin and protest risk. The highest-conviction signal is the sheer size of the award, which is material relative to Booz Allen's annual revenue.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 23, 2026

The two contracts analyzed total $1.19 billion in obligations, both awarded to civilian agencies (General Services Administration and NASA) with no defense-related awards, indicating a strong civilian space and administrative services focus. The dominant award is a $1.07 billion contract to Booz Allen Hamilton from the GSA, representing 90% of total value, though details on pricing, competition, and revenue impact are sparse. The second contract, a $120.3 million firm-fixed-price delivery order to Air Products and Chemicals from NASA for helium support at Kennedy Space Center, offers a stable multi-year revenue stream through 2025 with high execution certainty. The highest-conviction signal is the Air Products award due to its transparent terms and predictable cash flows, while the Booz Allen contract's lack of detail introduces uncertainty. Key risks include budget concentration on a single large award and potential vulnerability to continuing resolution impacts on NASA's space launch operations.

2 total filings
· daily

High-Value Federal Grants ($5M+) — July 23, 2026

The three contracts analyzed represent $1.28 billion in total obligations, with a 1/3 defense-related split (the $1.07B Booz Allen Hamilton award dominates). The dominant theme is stable, multi-year government spending on critical infrastructure and biodefense R&D, with the highest-conviction signal being Booz Allen Hamilton's $1.07B defense contract from GSA, which is highly material to the company's revenue base. Key risks include execution risk on Air Products' fixed-price helium contract and high pricing risk on IAVI's fixed-price vaccine R&D contract, which could pressure margins. Investors should watch for option exercises on the Air Products and IAVI contracts as catalysts for upside.

3 total filings
· daily

General Federal Contracts — July 23, 2026

This digest covers $1.28 billion in federal obligations from July 23, 2026, with a 1/3 defense-related split (one contract) and a dominant civilian theme from NASA and HHS. The highest-conviction signal is Booz Allen Hamilton's $1.07 billion sole-source defense contract from GSA, representing 83% of total value and signaling strong competitive moat in defense consulting. A key risk is the fixed-price R&D nature of IAVI's $95.6 million HHS contract, which transfers cost overrun risk to the nonprofit. The aggregate average signal strength of 6.3/10 reflects moderate conviction, with the Booz Allen award being the primary bullish driver.

3 total filings
· daily

All NASA Contracts — July 23, 2026

This digest covers a single NASA contract awarded to Air Products and Chemicals, Inc. valued at $120.3 million (with options up to $172.0 million), representing a purely civilian, non-defense award. The dominant theme is NASA's sustained investment in critical launch infrastructure at Kennedy Space Center, specifically helium supply for propellant and support operations. The highest-conviction signal is the high execution certainty: $120.2 million of the base obligation has already been outlayed, indicating a stable, multi-year revenue stream for Air Products. A key risk is the medium pricing risk inherent in the firm-fixed-price structure, though the company's competitive win in a full-and-open competition suggests pricing discipline.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 23, 2026

The S&P 500 Technology sector is showing a clear divergence between top-line growth and profitability, with two major software companies—ServiceNow and IBM—reporting mixed Q2 2026 results. ServiceNow posted impressive 24% YoY revenue growth, driven by 24.5% subscription gains, but saw operating income plunge 54.7% due to a 64.8% surge in subscription costs, signaling aggressive reinvestment. IBM's revenue grew a modest 1.1% YoY, but gross margins contracted 110 bps and net income fell 1.3%, while cash flow improved 27.9%—a classic 'growth vs. efficiency' tension. Both companies are deploying significant capital: IBM spent $10.5B on acquisitions in H1, and ServiceNow added $7.5B in debt to fund an $8.8B M&A spree, raising leverage concerns. Insider activity at Salesforce is routine and non-alarming, with two executives exercising RSUs and having shares withheld for taxes, indicating no conviction signal. The overarching theme is that tech giants are prioritizing market share and AI investment over near-term margins, a pattern that demands close monitoring of cash burn and debt serviceability.

4 high priority 4 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 23, 2026

The NASDAQ-100 filings for July 23, 2026, reveal a divergent earnings landscape: while Alphabet and Intel posted strong top-line growth (24% and 25% YoY, respectively), profitability pressures are acute across the cohort, with Tesla's operating income collapsing 57% and Comcast's net income dropping 68% due to one-time items. Insider selling is a notable theme, with CoreWeave's CEO unloading $5M in stock and a Strategy director selling, signaling potential management caution. Capital allocation is bifurcated: T-Mobile aggressively repurchased $7.1B in shares, while Comcast paused buybacks ahead of its spin-off. Forward-looking guidance from Intel and T-Mobile points to continued AI-driven demand, but GAAP losses and rising leverage (Alphabet's long-term debt doubled) warrant close monitoring. The mixed sentiment across 8 of 10 filings underscores a market grappling with revenue growth versus margin compression and strategic transitions.

6 high priority 4 medium 10 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 23, 2026

This digest of 40 activist and institutional filings reveals a day dominated by passive ownership updates and significant corporate restructuring. The most critical development is the escalation of an activist campaign at Braemar Hotels & Resorts, where top shareholder Al Shams Investments has publicly accused the Chairman of 'outrageous profiteering' and plans to solicit proxies, signaling a high-stakes governance battle. Concurrently, a major theme of corporate simplification is emerging from the Brookfield complex, with three separate filings detailing proposals to merge its renewable and infrastructure entities into single publicly traded companies, with shareholder votes scheduled for October 14, 2026. While most filings are routine 13G amendments showing passive positions, several notable insider transactions and stake changes were identified, including a significant reduction in position by Olesen Value Fund at Solitron Devices and a new activist stance by Glenbrook Capital at SenesTech. The data also highlights a cluster of Israeli and Israeli-linked companies (Camtek, Tower Semiconductor, TAT Technologies, Enlight Renewable Energy) where Migdal Insurance has disclosed passive stakes, suggesting a regional institutional focus. Overall, the period shows a market with high passive ownership stability punctuated by targeted activist interventions and complex corporate actions.

15 high priority 25 medium 40 total filings